Brind.
  1. Sana Biotechnology reported financial results and received FDA feedback on its IND filing.
  2. Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.

Sana Biotechnology delivered encouraging six-month data on its allogeneic CAR-T platform for Type 1 diabetes.

2 reports, 2 independent Updated Aug 1
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Sana Biotechnology delivered encouraging six-month data on its allogeneic CAR-T platform for Type 1 diabetes.

Who's involved

What this event is mainly about
Sana Biotechnology

How it developed

Newest first. Tap a step to see who reported it.
  1. Sana Biotechnology highlighted UP421 clinical data for Type 1 diabetes care.1 source
  2. Encouraging six-month data released on 2025-07-23 regarding the allogeneic CAR-T platform for T1D.1 source

Keep exploring

Part of

Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital. All 2 developments

Within Sana Biotechnology reported financial results and received FDA feedback on its IND filing.

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • Insider MonkeyCiti Maintained a Buy Rating on Sana Biotechnology (SANA) Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the Best American Penny Stocks to Buy According to Analysts. On July 2, Citi analyst Samanth